Antifibrotic Research

B7-33

InvestigationalLongevity & cellular
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is B7-33?

B7-33 is a preclinical single-chain relaxin-family peptide agonist studied for selective antifibrotic signaling in animal models. Human safety and effectiveness have not been established.

Dosing as published

No approved-label or study protocol is recorded for B7-33 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalInvestigational
CompoundingEligibility not established.
Last checked2026-07-13
Next review2027-01-09

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.